New pill takes on Hard-to-Treat prostate cancer by targeting a key enzyme and boosting immunity
Disease control
Recruiting now
This study tests a new daily pill, (R)-9bMS, for men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has stopped responding to standard hormone treatments. The drug works by blocking a protein called ACK1 and also helps the immune system fight the tumor.…
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC